leisure time -WSS

leisure time

author：fashion 2025-10-01 14:17:17 - browse：76499

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Report: NIH

hotspot

leisure time

WSS

Prosthetic arm enables patients to feel the objects they grip

Biogen joins immunology wave with $1.15 billion acquisition of HI

Fentanyl is making it harder to start addiction treatment

Scientists successfully use ultrasound imaging to map brain activity

Addressing health care workers' trauma can help fight burnout

Cue Health, Covid

Wikipedia

leisure time

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Eyeing GLP

Anesthesiologist group: stop taking Ozempic before surgery

ASCO eve: Let’s set the table for this year's meeting

Apple is now the first public company to be valued at $3 trillion

Digital health: a case of mistaken identity

Heart attack and stroke risk calculators need revising

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Hepatitis C has a cure — but many Americans still lack access to it

Stigma and the return of syphilis

explore

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Lab trade group sues FDA to halt regulation of lab

Biohaven protein

Do more moles mean more problems? Not so, says new study

Questions and answers about ramping up H5N1 bird flu vaccine

Bird flu surveillance in wastewater gets boost from consortium

hotspot

hotspot

leisure time

Wikipedia